Benzinga | Dec 14, 2020 07:11AM EST

Arvinas Releases Interim Clinical Data for its PROTAC Protein Degraders ARV-471 and ARV-110

-- ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreated patient population



-- Initiation of a combination trial of ARV-471 and Ibrance(r) (palbociclib) expected this month; three additional trials of ARV-471 in patients with breast cancer expected to begin in 2021

-- ARV-110 continues to demonstrate a favorable safety profile, tolerability, and anti-tumor activity in a heavily pretreated patient population as Phase 1 dose escalation continues in parallel with the ARDENT Phase 2 expansion

-- The ARDENT Phase 2 expansion trial for ARV-110 is designed to evaluate the potential for accelerated approval in a molecularly defined population and broader approval in earlier mCRPC